No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
MEDP240517C410000
- 1.77
- -0.72-28.92%
15min DelayClose May 13 16:00 ET
3.02High1.51Low
3.02Open2.49Pre Close17 Volume437 Open Interest410.00Strike Price4.72KTurnover51.01%IV5.78%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry1.77Time Value100Contract SizeAmericanOptions Type0.1681Delta0.0124Gamma219.93Leverage Ratio-0.6738Theta0.0066Rho36.97Eff Leverage0.0996Vega
Intraday
- 5D
- 1D
News
Zacks.com Featured Highlights Medpace, American Axle, Diebold Nixdorf, Euronet and Omnicom
5 Stocks With Upgraded Broker Ratings Worth Investing in Now
Medpace(MEDP.US) 10% Shareholder Sells US$3.31 Million in Common Stock
$Medpace(MEDP.US)$ 10% Shareholder Troendle August J. sold 8,268 shares of common stock on May 8, 9, 2024 at an average price of $400.41 for a total value of $3.31 million.Source: Announcement What is
Medpace Holdings (MEDP) Rose as It Reported Strong Matrices
Investment management company Vulcan Value Partners recently released its first quarter 2024 investor letter.
(MEDP) - Analyzing Medpace Hldgs's Short Interest
Medpace Hldgs's (NYSE:MEDP) short percent of float has risen 3.92% since its last report. The company recently reported that it has 984 thousand shares sold short, which is 4.77% of all regular shares
Medpace(MEDP.US) 10% Shareholder Sells US$21.13 Million in Common Stock
$Medpace(MEDP.US)$ 10% Shareholder Troendle August J. sold 52,404 shares of common stock on May 6, 7, 2024 at an average price of $403.2 for a total value of $21.13 million.Source: Announcement What i
Comments
Investors expect Medpace Holdings to outperform the market, hence its high P/E ratio. Strong future growth anticipation makes investors pay more for the stock, supporting the share price.
The Price Is Right For Medpace Holdings, Inc. (NASDAQ:MEDP) 1
Medpace Holdings' robust conversion of profit to free cash flow is promising. Its underlying earnings potential may even surpass the statutory profit. Its earnings per share have seen a remarkable growth over the past three years.
1
Medpace Holdings' market sentiment remains steady, mirroring EPS growth. The stock's recent performance shows improvement, with a 90% shareholder return over the last year, surpassing the five-year TSR of 41% per year. The strong share price momentum suggests a closer look at the stock may be worthwhile.
Medpace's high P/E is backed by its forecast growth being higher than the wider market. Investors are quite confident in the company's future earnings and seem willing to pay more for the stock, suggesting a bullish outlook.
Insider selling at current price (US$274) is less worrying, but there were no purchases over the past year to boost confidence. A high level of insider ownership often implies interests of all shareholders are considered, though recent history of share sales triggers some hesitation.
Read more